Neuron-Specific Enolase (NSE)

When NSE is genuinely raised, it is most associated with small cell lung cancer and with neuroblastoma in children. The link is strong enough to be useful: research on serum NSE in small cell lung cancer found elevated levels in up to roughly 70% of patients at diagnosis, climbing to around 90% in extensive disease. Because the level correlates with tumor mass and metabolic activity, a value that falls with treatment and rises again later can flag shrinkage or recurrence before other signs appear.

That is the marker working as intended. The caution comes from what a single high number does not tell you. The NCI is explicit that tumor markers are not unique to cancer; they can also be produced by normal cells responding to cancer or to benign, noncancerous conditions. MedlinePlus frames the practical consequence plainly: these tests are used mainly to monitor treatment and watch for recurrence, not to diagnose cancer on their own. A first-ever NSE drawn on a healthy person who happens to score above the range is a prompt to look closer, not a verdict.

Here is the artifact that the standard fact sheets skip. The αγ form of enolase that NSE assays detect is stored in erythrocytes and platelets, and it is released the moment those cells break open. A study on correcting NSE in hemolyzed serum measured the effect directly: the false increment rose in step with the hemolysis index, following the relationship ΔNSE = 0.469 × H-index with a tight fit (R² of 0.864). The same work found the correction reliable only up to a hemolysis index of about 30 µmol/L, beyond which the sample should not be reported at all.

The unsettling part is how early this starts. A separate analysis found that hemoglobin concentrations as low as around 20 mg/dL already affect the NSE measurement, and that clinically meaningful false elevation occurs even when the hemolysis is invisible to the naked eye. That is why the recommendation is to assess the hemolytic index alongside every NSE result, including the samples that look perfectly clear. The contamination does not announce itself with a pink tinge.

There is one more place this number shows up, and it causes real confusion. The same NSE assay is used in intensive care to help predict neurological recovery after cardiac arrest, where ERC-ESICM guidance treats a level above 60 µg/L at 48 to 72 hours after circulation returns as one criterion among several for a poor outcome. That threshold has nothing to do with the outpatient reference range, and the same guidance lists hemolysis, blood transfusion, ECMO, and malignant tumors as confounders that falsely inflate it. If you saw the 60 figure online, it was not describing your tumor-marker report.

Because so much of NSE's noise is pre-analytical, the most useful actions happen around the draw rather than after it.

NSE rarely travels alone. It usually appears on a broader tumor-markers panel, alongside proteins like CEA for epithelial cancers, AFP for liver and germ-cell tumors, CA 19-9 for pancreatic and biliary disease, and CA 125 for ovarian monitoring. Each carries the same caveat NSE does: useful for following a known situation, unreliable as a standalone alarm. Our guide to reading tumor markers walks through that distinction in more depth.

For anyone whose NSE is being followed over time, the honest reading lives in the trajectory. A level that drops after treatment and stays down is reassuring in a way no single result can be, and a value creeping upward over months earns attention even while it sits inside the range. Since hemolysis can fake the whole rise, our guide to how reliable a lab result is covers why a marker this sensitive to handling only becomes trustworthy once the sample quality is accounted for.